Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rifapentine

FDA-approved product (tablet, oral), marketed as Priftin, Rifapentine.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Rifapentine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics
FDA pharmacologic class
Rifamycin Antimycobacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AB05; FDA class Rifamycin Antimycobacterial

Repurposing investigation

Rifapentine is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA98.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. A stereoisomer of this medicine was in the model's training data.
  • E. coli76.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis95.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. A stereoisomer of this medicine was in the model's training data.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Rifapentine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rifapentine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Novel Therapy With a 1-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB-YOUTH Study)

    NCT06022146 · start 2023-09-01

    Registered record
    Registry ID
    NCT06022146
    Conditions
    Tuberculosis; Latent Tuberculosis
    Interventions
    isoniazid and rifapentine; Rifampin and Isoniazid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-09-01
    Completion
    2026-09-01
    Enrolment
    3,520

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Latent Tuberculosis
    Interventionisoniazid and rifapentine; Rifampin and Isoniazid
    PhasePhase 3
    Registry statusRecruiting

  • Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients

    NCT05118490 · start 2023-07-19

    Registered record
    Registry ID
    NCT05118490
    Conditions
    HIV Seropositivity; Tuberculosis; Household Contact
    Interventions
    Daily rifapentine and isoniazid for 4 weeks; Weekly rifapentine and isoniazid for 12 weeks
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2023-07-19
    Completion
    2025-12-31
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Seropositivity; Tuberculosis; Household Contact
    InterventionDaily rifapentine and isoniazid for 4 weeks; Weekly rifapentine and isoniazid for 12 weeks
    PhasePhase 4
    Registry statusActive not recruiting

  • Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)

    NCT05122767 · start 2023-05-24

    Registered record
    Registry ID
    NCT05122767
    Conditions
    Tuberculosis; HIV
    Interventions
    Dolutegravir; 3HP
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2023-05-24
    Completion
    2025-12-31
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; HIV
    InterventionDolutegravir; 3HP
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)

    NCT05401071 · start 2023-01-13

    Registered record
    Registry ID
    NCT05401071
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    Short Regimen with Rifapentine 10mg/kg; Standardized Regimen; Short Regimen with Rifapentine 15mg/kg; Short Regimen with Rifapentine 20mg/kg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2023-01-13
    Completion
    2027-11-01
    Enrolment
    2,442

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionShort Regimen with Rifapentine 10mg/kg; Standardized Regimen; Short Regimen with Rifapentine 15mg/kg; Short Regimen with Rifapentine 20mg/kg
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • One-month Latent Tuberculosis Treatment for Renal Transplant Candidates

    NCT05411744 · start 2022-07-01

    Registered record
    Registry ID
    NCT05411744
    Conditions
    Latent Tuberculosis; End Stage Renal Disease; Renal Transplant Candidate for Right Kidney; Renal Transplant Candidate for Left Kidney
    Interventions
    1 month Rifapentine, Isoniazid and Vitamin B6
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2022-07-01
    Completion
    2029-06-30
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLatent Tuberculosis; End Stage Renal Disease; Renal Transplant Candidate for Right Kidney; Renal Transplant Candidate for Left Kidney
    Intervention1 month Rifapentine, Isoniazid and Vitamin B6
    PhasePhase 4
    Registry statusActive not recruiting

  • Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

    NCT04311502 · start 2021-11-05

    Registered record
    Registry ID
    NCT04311502
    Conditions
    HIV; Tuberculosis
    Interventions
    Rifapentine; Rifampicin; Isoniazid; Pyrazinamide; Ethambutol; Clofazimine loading dose; Clofazimine 100 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2021-11-05
    Completion
    2025-06-24
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Tuberculosis
    InterventionRifapentine; Rifampicin; Isoniazid; Pyrazinamide +3 more
    PhasePhase 2
    Registry statusTerminated

  • A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects

    NCT04551573 · start 2021-05

    Registered record
    Registry ID
    NCT04551573
    Conditions
    Tuberculosis; Hiv
    Interventions
    Rifapentine daily; Rifapentine weekly
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2021-05
    Completion
    2021-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Hiv
    InterventionRifapentine daily; Rifapentine weekly
    PhasePhase 4
    Registry statusWithdrawn

  • Short Course Rifapentine and Isoniazid for the Preventive Treatment for Latent Genital Tuberculosis

    NCT04528277 · start 2020-09-01

    Registered record
    Registry ID
    NCT04528277
    Conditions
    Infertility, Female; Recurrent Implantation Failure; Genital Tuberculoses, Female; Genital Tuberculosis, Latent
    Interventions
    rifapentine plus isoniazid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2020-09-01
    Completion
    2022-09-01
    Enrolment
    1,050

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility, Female; Recurrent Implantation Failure; Genital Tuberculoses, Female; Genital Tuberculosis, Latent
    Interventionrifapentine plus isoniazid
    PhasePhase 3
    Registry statusUnknown

  • Options for Delivering Isoniazid-Rifapentine (3HP) for TB Prevention (3HP Options Implementation Trial)

    NCT03934931 · start 2020-07-13

    Registered record
    Registry ID
    NCT03934931
    Conditions
    Tuberculosis; Latent Tuberculosis; HIV/AIDS
    Interventions
    Streamlined weekly DOT visits; Weekly DOT visit reminders; Cost reimbursement DOT; 99DOTS; Weekly SAT dosing reminders/check-ins; Cost reimbursement SAT
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-07-13
    Completion
    2025-01-13
    Enrolment
    1,656

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Latent Tuberculosis; HIV/AIDS
    InterventionStreamlined weekly DOT visits; Weekly DOT visit reminders; Cost reimbursement DOT; 99DOTS +2 more
    PhaseNot applicable
    Registry statusCompleted

  • Tuberculosis Clinical Trials Consortium Study 35

    NCT03730181 · start 2019-11-12

    Registered record
    Registry ID
    NCT03730181
    Conditions
    Latent Tuberculosis
    Interventions
    Rifapentine; Isoniazid
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2019-11-12
    Completion
    2025-05-15
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLatent Tuberculosis
    InterventionRifapentine; Isoniazid
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI

    NCT03474029 · start 2019-08-01

    Registered record
    Registry ID
    NCT03474029
    Conditions
    Latent Tuberculosis
    Interventions
    Rifapentine daily for 6 weeks; Rifapentine and Isoniazid weekly for 12 weeks; Rifampin and Isoniazid daily for 12 weeks; Rifampin daily for 16 weeks
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2019-08-01
    Completion
    2029-12-31
    Enrolment
    3,400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLatent Tuberculosis
    InterventionRifapentine daily for 6 weeks; Rifapentine and Isoniazid weekly for 12 weeks; Rifampin and Isoniazid daily for 12 weeks; Rifampin daily for 16 weeks
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Short Course Rifapentine and Isoniazid for the Preventive Treatment of Tuberculosis(SCRIPT-TB)

    NCT03900858 · start 2018-12-01

    Registered record
    Registry ID
    NCT03900858
    Conditions
    Silicosis Tuberculosis
    Interventions
    Isoniazid；Rifapentine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2018-12-01
    Completion
    2022-06-01
    Enrolment
    566

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSilicosis Tuberculosis
    InterventionIsoniazid；Rifapentine
    PhaseNot applicable
    Registry statusUnknown

  • Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)

    NCT03510468 · start 2018-06-12

    Registered record
    Registry ID
    NCT03510468
    Conditions
    Healthy Volunteers
    Interventions
    Tenofovir alafenamide; Rifapentine; Isoniazid (INH); Pyridoxine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-06-12
    Completion
    2022-12-21
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionTenofovir alafenamide; Rifapentine; Isoniazid (INH); Pyridoxine
    PhasePhase 1
    Registry statusCompleted

  • Latent Tuberculosis in Type 2 Diabetes

    NCT06874725 · start 2018-04-18

    Registered record
    Registry ID
    NCT06874725
    Conditions
    Latent Tuberculosis Infection
    Interventions
    Rifapentine and Isoniazid for 3 months; Isoniazid (INH) daily for 9 months
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2018-04-18
    Completion
    2025-04-18
    Enrolment
    552

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLatent Tuberculosis Infection
    InterventionRifapentine and Isoniazid for 3 months; Isoniazid (INH) daily for 9 months
    PhasePhase 4
    Registry statusActive not recruiting

  • Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis

    NCT03474198 · start 2018-03-21

    Registered record
    Registry ID
    NCT03474198
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    Rifampicin; Isoniazid; Pyrazinamide; Ethambutol; Linezolid; Clofazimine; Rifapentine; Levofloxacin; Bedaquiline; Rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2018-03-21
    Completion
    2022-01-20
    Enrolment
    675

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionRifampicin; Isoniazid; Pyrazinamide; Ethambutol +6 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted